Life Science Invest Fund to head Lipidor AB nomination committee

It is with great pleasure we can announce that Jan Poulsen, CEO of Life Science Invest Fund (LSIF) has been elected as chairman of the nomination committee. Lipidor AB is in phase III with APK02 which can significantly improve the lives of patients with psoriasis. The phase III result is expected towards end of Q1 2025 and will by a positive outcome completely transform Lipidor AB. The AGM 2025 thus holds important decisions to be made.